Fox Run Management L.L.C. Invests $181,000 in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Fox Run Management L.L.C. purchased a new stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 20,185 shares of the biotechnology company’s stock, valued at approximately $181,000.

Several other hedge funds have also made changes to their positions in the company. SBI Securities Co. Ltd. acquired a new stake in Aurinia Pharmaceuticals during the 4th quarter valued at $25,000. Blue Trust Inc. raised its position in Aurinia Pharmaceuticals by 3,041.4% during the fourth quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 6,174 shares during the period. FMR LLC lifted its stake in Aurinia Pharmaceuticals by 44.8% in the 3rd quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock worth $93,000 after acquiring an additional 3,919 shares in the last quarter. Virtu Financial LLC acquired a new stake in Aurinia Pharmaceuticals during the 4th quarter worth about $96,000. Finally, Union Bancaire Privee UBP SA purchased a new position in Aurinia Pharmaceuticals during the 4th quarter valued at about $108,000. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Price Performance

Shares of NASDAQ:AUPH opened at $8.29 on Friday. The firm has a market cap of $1.14 billion, a price-to-earnings ratio of -55.26 and a beta of 1.26. Aurinia Pharmaceuticals Inc. has a 1 year low of $4.71 and a 1 year high of $10.67. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17. The business has a fifty day simple moving average of $8.09 and a 200 day simple moving average of $8.03.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday.

Insider Transactions at Aurinia Pharmaceuticals

In other news, COO Matthew Maxwell Donley sold 65,902 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total transaction of $527,216.00. Following the transaction, the chief operating officer now owns 739,456 shares in the company, valued at $5,915,648. This represents a 8.18 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Peter Greenleaf sold 195,593 shares of Aurinia Pharmaceuticals stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total transaction of $1,564,744.00. Following the completion of the sale, the chief executive officer now directly owns 1,953,892 shares of the company’s stock, valued at approximately $15,631,136. The trade was a 9.10 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 343,898 shares of company stock valued at $2,753,094 in the last three months. Corporate insiders own 4.30% of the company’s stock.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.